Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Literature
1.
Ergün EL, Caglar M, Bozkurt MF, Ergün H. 99mTc sestamibi myocardial perfusion scintigraphy with the novel use of metamizol for the detection of perfusion reversibility. Eur J Nucl Med Mol Imaging 2008;35:1530–6.PubMedCrossRef
2.
Cuocolo A, Pace L, Ricciardelli B, Chiariello M, Trimarco B, Salvatore M. Identification of viable myocardium in patients with chronic coronary artery disease: comparison of thallium-201 scintigraphy with reinjection and technetium-99m-methoxyisobutyl isonitrile. J Nucl Med 1992;33:505–11.PubMed
3.
Marzullo P, Sambuceti G, Parodi O. The role of sestamibi scintigraphy in the radioisotopic assessment of myocardial viability. J Nucl Med 1992;33:1925–30.PubMed
4.
Sawada SG, Allman KC, Muzik O, Beanlands RS, Wolfe ER Jr, Gross M, et al. Positron emission tomography detects evidence of viability in rest technetium-99m sestamibi defects. J Am Coll Cardiol 1994;23:92–8.PubMedCrossRef
5.
Sciagrà R, Bisi G, Santoro GM, Zerauschek F, Sestini S, Pedenovi P, et al. Comparison of baseline-nitrate technetium-99m sestamibi with rest-redistribution thallium-201 tomography in detecting viable hibernating myocardium and predicting post-revascularization recovery. J Am Coll Cardiol 1997;30:384–91.PubMedCrossRef
6.
Leoncini M, Sciagrà R, Bellandi F, Maioli M, Sestini S, Marcucci G, et al. Low-dose dobutamine nitrate-enhanced technetium 99m sestamibi gated SPECT versus low-dose dobutamine echocardiography for detecting reversible dysfunction in ischemic cardiomyopathy. J Nucl Cardiol 2002;9:402–6.PubMedCrossRef
7.
Russell RR, Zaret LB. Nuclear cardiology: present and future. Curr Probl Cardiol 2006;31:557–629.PubMedCrossRef
8.
Hesse B, Tägil K, Cuocolo A, Anagnostopoulos C, Bardies M, Bax J, et al. EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology. Eur J Nucl Med 2005;32:855–97.CrossRef
9.
Georgoulias P, Demakopoulos N, Kontos A, Xaplanteris P, Xydis K, Fezoylidis I. Early post-stress pulmonary uptake of 99mTc tetrofosmin during exercise (SPECT) myocardial perfusion imaging: correlation with haemodynamic, perfusion and function parameters. Nucl Med Commun 2006;27:119–26.PubMedCrossRef
10.
Georgoulias P, Demakopoulos N, Orfanakis A, Xydis K, Xaplanteris P, Vardas P, et al. Evaluation of abnormal heart-rate recovery after exercise testing in patients with diabetes mellitus: correlation with myocardial SPECT and chronotropic parameters. Nucl Med Commun 2007;28:165–71.PubMedCrossRef
11.
Jensen KM, Dahl JB. Plasma concentrations of glyceryl trinitrate and its dinitrate metabolites after sublingual administration to volunteers. Simultaneous determination of glyceryl trinitrate and its dinitrate metabolites. Arzneimittelforschung 1994;44:951–3.PubMed
Metadata
Title
Drug enhancement of myocardial tracer uptake during myocardial perfusion imaging
Authors
Panagiotis Georgoulias
Varvara Valotassiou
Ioannis Tsougos
Publication date
01-01-2009
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2009
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-008-0974-z

Other articles of this Issue 1/2009

European Journal of Nuclear Medicine and Molecular Imaging 1/2009 Go to the issue

Original Article

Usefulness of competitive inhibitors of protein binding for improving the pharmacokinetics of 186Re-MAG3-conjugated bisphosphonate (186Re-MAG3-HBP), an agent for treatment of painful bone metastases

Focus on

Beyond haematuria in uro oncology: imaging biomarkers lag behind needs

Original Article

Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts

Original Article

Recombinant carcinoembryonic antigen as a reporter gene for molecular imaging

Original Article

Prospective dosimetry with 99mTc-MDP in metabolic radiotherapy of bone metastases with 153Sm-EDTMP

Society Communications

Society communications